about
Humoral-targeted immunotherapies in multiple sclerosisBone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistanceSuppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster.The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation.Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disordersPost-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?Mechanisms of action of CD20 antibodies.Novel reduction-sensitive micellar nanoparticles assembled from Rituximab-doxorubicin conjugates as smart and intuitive drug delivery systems for the treatment of non-Hodgkin's lymphoma.Controlled and Targeted Drug Delivery by a UV-responsive Liposome for Overcoming Chemo-resistance in Non-Hodgkin Lymphoma.Adoptive T Cell Immunotherapy for Patients with Primary Immunodeficiency Disorders.Neutralizing anti-gH antibody of Varicella-zoster virus modulates distribution of gH and induces gene regulation, mimicking latency.The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.Interaction of Immunoglobulin with Cytomegalovirus-Infected Cells.The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis.Imaging and measuring the molecular force of lymphoma pathological cells using atomic force microscopy.ImmunoPET of Malignant and Normal B Cells with 89Zr- and 124I-Labeled Obinutuzumab Antibody Fragments Reveals Differential CD20 Internalization In Vivo.Anti-erythropoietin receptor antibody-associated pure red cell aplasia accompanied by Coombs-negative autoimmune hemolytic anemia in a patient with T cell/histiocyte-rich large B cell lymphoma.FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy.Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics.Ofatumumab (Arzerra®): a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity
P2860
Q26865971-78411C02-22E6-404A-95C7-4E2E67A07B6EQ28243054-0A3D777E-F3F2-4EA0-8055-439A0F3C457BQ36414417-D422FAF7-403C-424D-950D-FE1C9BF9B9E7Q36967153-0E44A77C-7F05-468D-AC49-BADF219190DFQ37146688-2B20A3FF-9D00-4EAC-924D-D748467B301CQ37265471-62A4A538-F38F-4889-A3E5-C622DEFD8BA0Q37919869-0A39E4AC-2386-4444-A1B1-28E7AC559542Q38066195-A7F502C1-3ABA-4B44-8CFE-ABA5CCAA9E18Q38706179-06E68DFC-6C7A-4A6A-A200-73FF6FAB8B41Q38903528-C792C3AE-487C-4B07-A758-F4B489BCE040Q39100204-A390E77A-B5EF-45D8-A1F3-D6AD68CD58C1Q39532117-A67DF72A-C2A6-4D98-8062-E7D8D5F796D5Q39538318-F5377D05-7C46-4685-8943-1F9D836624BCQ40166218-70FDB9D8-919B-44DE-80A0-3D5CF8AD881BQ40230124-9D1B287B-E1BD-480B-A990-FBC7AC12886BQ44369173-89D85ECB-BC93-4215-B7DD-6E0ECA12921BQ46060208-B768AF41-1165-43D1-AF38-CF770FB9377BQ50463392-764CBF6C-6F8C-46FF-8D76-5611956141C0Q53688633-320555BC-B720-460E-BE7D-0C635E72FDCFQ55052715-C3406EEF-01DB-401E-9050-CE49A8D1638CQ56908538-C33C76AD-2860-4EFB-8E62-7A3C9130B633
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Antigenic modulation and rituximab resistance.
@ast
Antigenic modulation and rituximab resistance.
@en
type
label
Antigenic modulation and rituximab resistance.
@ast
Antigenic modulation and rituximab resistance.
@en
prefLabel
Antigenic modulation and rituximab resistance.
@ast
Antigenic modulation and rituximab resistance.
@en
P2860
P1476
Antigenic modulation and rituximab resistance.
@en
P2093
Margaret A Lindorfer
Ronald P Taylor
P2860
P304
P356
10.1053/J.SEMINHEMATOL.2010.01.006
P577
2010-04-01T00:00:00Z